Taiwan FDA registration 90ccb2c4d151731ee5510278b9784f4e
Liquichek Whole Blood Immunosuppressant Control
TW: 立可測 全血免疫抑制品管液
Taiwan·Risk Class 2·MD·BIO-RAD LABORATORIES·Registered Aug 26, 2013 – Aug 26, 2028ActiveRegistration details
- Analysis ID
- 90ccb2c4d151731ee5510278b9784f4e
- License Form
- Ministry of Health Medical Device Import No. 025270
- Customs Code
- DHA05602527006
Company information
- Manufacturer
- BIO-RAD LABORATORIES
- Manufacturer Country
- United States
- Authorized Representative
- Bio-Rad Laboratories Inc., Taiwan Branch (U.S.A.)
Product details
- Intended Use
- This product is an analysed controlled substance intended to monitor the precision of laboratory testing procedures for analytes in the table: Cyclosporine, Everolimus, Sirolimus, Tacrolimus.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A1660 Quality Control Materials (Analytical and Non-Analytical)
- Import Information
- Imported from abroad
Dates and status
- Registration Date
- Aug 26, 2013
- Expiry Date
- Aug 26, 2028
About this record
Access comprehensive regulatory information for Liquichek Whole Blood Immunosuppressant Control in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 90ccb2c4d151731ee5510278b9784f4e and manufactured by BIO-RAD LABORATORIES. The authorized representative in Taiwan is Bio-Rad Laboratories Inc., Taiwan Branch (U.S.A.).
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices